Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc. V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.


TSXV:KNE - Post by User

Kane Biotech Inc. > New Press Release - Kane Biotech Receives Offer for its Interest in STEM Animal Health
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(102)
•••
Comment by francoisl13on Mar 18, 2024 3:36pm
43 Views
Post# 35938970

RE:RE:RE:RE:RE:New Press Release - Kane Biotech Receives Offer for its Interest in STEM Animal Health

RE:RE:RE:RE:RE:New Press Release - Kane Biotech Receives Offer for its Interest in STEM Animal HealthKNE said that they were going to do everything possible to finalize the sales of their participation in STEM within 90 days, it was on December 20th so...March 20th is the 90th days since the announcement. It would make a lot of sense to finalize everything before the end of the QTR. Let's hope for the good news to be announced before Friday March 29th.
I wonder if they will ask for a trading halt....
Once done, an update will be required for the following;
1. Revyve orders and production level;
2. DispersinB wound gel clinical trials;
3. DispersinB acne trials with UofMiami;
4. Update on Revyve approval process in South America (Salud Pharma)
GLTA

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities